MUMBAI, India, Nov. 14 -- Intellectual Property India has published a patent application (202517068248 A) filed by Akagera Medicines, Inc., Boxford, U.S.A., on July 17, for 'lipid nanoparticles for the prevention of tuberculosis or other mycobacterial infections.'
Inventor(s) include Fulton, Ross; Drummond, Daryl, C; Friedman, Robin; Cobaugh, Christian; and Hayes, Mark, E.
The application for the patent was published on Nov. 14, under issue no. 46/2025.
According to the abstract released by the Intellectual Property India: "Aspects of the present disclosure provides for improved mycobacterium tuberculosis vaccine compositions of ionizable lipid nanoparticles for the delivery of immunogenic nucleic acids to cells. Anionic phospholipids, including phosphatidyl serine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in dendritic cells. In some embodiments, the incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation provided high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Other aspects of the present disclosure provide mRNA that encodes for concatenated peptides encoding for multiple MHC-II tuberculosis epitopes, and optionally includes a second mRNA encoding for concatenated MHC-I tuberculosis epitopes."
The patent application was internationally filed on Dec. 22, 2023, under International application No.PCT/US2023/085680.
Disclaimer: Curated by HT Syndication.
